|Bid||27.01 x 1300|
|Ask||27.09 x 1000|
|Day's Range||26.13 - 27.17|
|52 Week Range||17.05 - 76.80|
|Beta (3Y Monthly)||1.85|
|PE Ratio (TTM)||45.72|
|Earnings Date||Apr 24, 2017 - Apr 28, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.33|
IntriCon (IIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Attractive stocks have exceptional fundamentals. In the Read More...
Several board members and executives exercised various options to acquire thousands of IntriCon shares — often at a fraction of the market price — just a few days before selling shares to the company.
IntriCon Corporation (IIN), a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices, today announced that it has hired Doug Pletcher as Vice President of Medical Business Development. Pletcher has more than 25 years of executive management and business development experience in the medical device industry. In this new role, Pletcher is responsible for sales and marketing of new product platforms into the medical biotelemetry market.
IntriCon Corporation (NASDAQ:IIN), which is in the medical equipment business, and is based in United States, saw a decent share price growth in the teens level on the NasdaqGM over Read More...
Anyone researching IntriCon Corporation (NASDAQ:IIN) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors Read More...
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was IntriCon Corporation (NASDAQ:IIN). Is IntriCon Corporation (NASDAQ:IIN) the right investment […]
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
Ligand Pharmaceuticals Inc (NASDAQ:LGND) is a unique type of biotech company. Instead of looking to take a drug or a family of drugs through the entire “lab-to-fab” product development process, LGND focuses on drug discovery, early stage drug development and product reformulation. This is the new age of biotech companies, and LGND is a prime example of how it should be done.
IntriCon Corporation , a designer, developer, manufacturer and distributor of body-worn devices, today announced that Mark Gorder, president and chief executive officer, will present at the Stifel 2018 Healthcare Conference at The Lotte New York Palace Hotel in New York City on Wednesday, Nov.
Every investor in IntriCon Corporation (NASDAQ:IIN) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in Read More...
IntriCon (IIN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IntriCon, which for years has done well selling components to hearing-aid-makers, has ambitious plans to shake up a rapidly consolidating market. "We’ve spent the past 10 years preparing ourselves," an executive said.
Today I will take a look at IntriCon Corporation’s (NASDAQ:IIN) most recent earnings update (30 June 2018) and compare these latest figures against its performance over the past few years,Read More...
IntriCon Corporation (IIN), a designer, developer, manufacturer and distributor of body-worn devices, today announced the completion of its previously announced underwritten public offering of 1,725,000 shares of its common stock, including 225,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All shares in the offering were sold by IntriCon at a price to the public of $55.00 per share. Net proceeds from the offering, including pursuant to the option exercise, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $88.9 million.